Research Topics
Species | Paola A GehrigSummaryAffiliation: University of North Carolina Country: USA Publications
| Collaborators
|
Detail Information
Publications
What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman?Paola A Gehrig
Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Gynecol Oncol 111:41-5. 2008..We sought to compare minimally invasive surgical techniques for staging the obese and morbidly obese woman with endometrial cancer...- Promising novel therapies for the treatment of endometrial cancerPaola A Gehrig
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7572, USA
Gynecol Oncol 116:187-94. 2010..While the majority of women with endometrial cancer enjoy a relatively good prognosis, the options for those women who suffer from a disease recurrence are limited and there is a need to identify novel agents... 
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancerAngeles Alvarez Secord
Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
Gynecol Oncol 107:285-91. 2007..We sought to determine the outcome of patients with advanced stage endometrial cancer treated with postoperative chemotherapy+/-radiation to determine whether there was an advantage to combining treatment modalities...- An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)Amanda Nickles Fader
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Cleveland Clinic, Cleveland, OH, USA
Gynecol Oncol 115:244-8. 2009..However, clinicopathologic risk factors for recurrence are not well understood. This study was undertaken to define the prognostic factors for recurrence and survival in patients with early-stage UPSC... - Multicenter analysis of recurrence and survival in stage IIIA endometrial cancerLaura J Havrilesky
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Cente, Durham, North Carolina 27710, USA
Gynecol Oncol 114:279-83. 2009..To determine factors related to recurrence and survival in women with stage IIIA endometrial cancer; to examine outcomes of women with IIIA1 disease... - Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomesAmanda Nickles Fader
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 81, Cleveland, Ohio 44195, USA
Gynecol Oncol 112:558-62. 2009..To determine recurrence patterns and survival outcomes of stage II uterine papillary serous carcinoma (UPSC) patients treated by various modalities with an emphasis on carboplatin/paclitaxel-based chemotherapy (CT)+/-radiotherapy (RT)... 
Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosisAaron Shafer
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina 27599 7572, USA
Int J Cancer 126:1144-54. 2010..This suggests that the combination of rapamycin and paclitaxel may be a promising effective targeted therapy for endometrial cancer...- Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathwayRabbie K Hanna
University of North Carolina, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Chapel Hill, NC, USA
Gynecol Oncol 125:458-69. 2012..To examine the effects of combination therapy with metformin and paclitaxel in endometrial cancer cell lines... - Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrestVictoria L Bae-Jump
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB# 7570, Chapel Hill, NC 27599, USA
Gynecol Oncol 100:487-94. 2006..CONCLUSIONS: Our data suggest that rapamycin may potentially exert its anti-tumor effects through two independent pathways by G1 cell cycle arrest as well as suppression of telomerase activity by inhibition of hTERT mRNA transcription... - A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomyJohn F Boggess
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA
Am J Obstet Gynecol 199:360.e1-9. 2008..The purpose of this study was to compare outcomes in women who underwent endometrial cancer staging by different surgical techniques... - Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatmentVictoria L Bae-Jump
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Gynecol Oncol 119:579-85. 2010..Our goal was to evaluate the effect of rapamycin, an mTOR inhibitor, in type I and II human endometrial cancer tumor explants... - Synergistic effect of rapamycin and cisplatin in endometrial cancer cellsVictoria L Bae-Jump
Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA
Cancer 115:3887-96. 2009..Because rapamycin is known to enhance the cytotoxicity of chemotherapeutic drugs, the authors' goal was to examine the effects of rapamycin and cisplatin in endometrial cancer cell lines... - Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended follow-upElizabeth N Skinner
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC 27599, USA
Gynecol Oncol 98:59-62. 2005..Given the lack of side effects and the potential for extending the PFS of those treated, a prospective randomized study of weekly paclitaxel should be considered... - Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategyLeigh A Cantrell
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, CB 7572, Chapel Hill, NC 27599 7572, USA
Gynecol Oncol 116:92-8. 2010..In order to better understand metformin's anti-tumorigenic potential, our goal was to assess the effect of metformin on proliferation and expression of key targets of metformin cell signaling in endometrial cancer cell lines... - Survival outcomes for women undergoing type III robotic radical hysterectomy for cervical cancer: a 3-year experienceLeigh A Cantrell
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC 27599 7572, USA
Gynecol Oncol 117:260-5. 2010..Longer follow-up is needed, but early data are supportive of at least equivalent oncologic outcomes compared with other surgical modalities... - Outcomes in surgical stage I uterine papillary serous carcinomaLaura J Havrilesky
Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 105:677-82. 2007..The optimal management of patients with stage I uterine papillary serous carcinoma (UPSC) is unclear. We sought to determine whether outcomes of women with surgical stage I UPSC differ with and without adjuvant therapy... - The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levelsChunxiao Zhou
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, CB# 7570, Chapel Hill, NC 27599, USA
Gynecol Oncol 101:305-10. 2006..Thus, loss of PTEN may allow endometrial cells to continue to express high levels of telomerase activity, facilitating the neoplastic transformation of the endometrium... - A case-control study of robot-assisted type III radical hysterectomy with pelvic lymph node dissection compared with open radical hysterectomyJohn F Boggess
Division of Gynecology Oncology, Department of Obstetrics and Gynecology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Am J Obstet Gynecol 199:357.e1-7. 2008..The purpose of this study was to compare robotically assisted hysterectomy (RAH) with open (ORH) type III radical hysterectomy in the treatment of early-stage cervical cancer... - Perioperative outcomes of robotically assisted hysterectomy for benign cases with complex pathologyJohn F Boggess
Department of Obstetrics and Gynecology, Division of Gynecology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Obstet Gynecol 114:585-93. 2009..To report on the perioperative outcomes after robotically assisted total hysterectomy for benign indications in a large patient population with predominantly complex pathology... - Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?David M Boruta
Department of Obstetrics and Gynecology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina 27599, USA
Cancer 101:2214-21. 2004.... - Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy?William J Lowery
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, NC 27710, USA
Gynecol Oncol 126:12-5. 2012..We sought to evaluate the effect of systematic lymphadenectomy (LND) on endometrial cancer-specific survival in an elderly population... - Arsenic trioxide (As2O3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cellsVictoria L Bae-Jump
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Reprod Sci 15:1011-7. 2008..Thus, As(2)O(3) may be valuable for its anti-estrogenic activity in combination with its anti-tumorigenic effects and be a novel therapeutic agent for endometrial cancer... - Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinomaAmanda Nickles Fader
Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, Ohio, USA
Cancer 115:2119-27. 2009..A study was undertaken to determine recurrence patterns and survival outcomes of stage I uterine papillary serous carcinoma (UPSC) patients... - Microscopic evaluation of lymph-node-bearing tissue in early-stage cervical cancer: a dual-institution reviewMichael R Milam
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Louisville Medical Center, Louisville, KY, USA
Ann Surg Oncol 17:1106-10. 2010..D. Anderson Cancer Center (MDACC) and the University of North Carolina (UNC)... - Induction of apoptosis and inhibition of telomerase activity by arsenic trioxide (As2O3) in endometrial carcinoma cellsChunxiao Zhou
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, CB 7570 MacNider Building, Chapel Hill, NC 27599 7570, USA
Gynecol Oncol 105:218-22. 2007..To examine the effects of arsenic trioxide (As2O3) on human endometrial carcinoma cell lines with respect to cytotoxicity and the induction of apoptosis and telomerase expression in vitro... - Estrogen-receptor-dependent regulation of telomerase activity in human endometrial cancer cell linesJohn F Boggess
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Gynecol Oncol 103:417-24. 2006.... - Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology GroupGregory Sutton
St Vincent Hospitals and Health Services, Division of Gynecologic Oncology, 8301 Harcourt Road, Suite 202, Indianapolis, IN 46260, USA
Gynecol Oncol 100:349-54. 2006..To evaluate outcome in patients with clinical stage I/II papillary serous (PS) or clear cell (CC) endometrial carcinoma treated with whole abdominal radiotherapy... - A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcomaLeigh A Cantrell
Division of Gynecologic Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
Gynecol Oncol 127:22-6. 2012..To evaluate the impact of adjuvant post-operative therapy in women with early stage uterine carcinosarcoma... - Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancerRobin A Laskey
Department of Obstetrics and Gynecology, Duke University Medical Center, USA
Gynecol Oncol 125:625-30. 2012..To identify factors that increase the risk of neutropenic events in women with advanced ovarian carcinoma receiving initial chemotherapy... - Physical strain and urgent need for ergonomic training among gynecologic oncologists who perform minimally invasive surgeryJason Franasiak
Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7570, USA
Gynecol Oncol 126:437-42. 2012..There is limited data regarding physical strain and minimally invasive gynecologic surgery (MIS). We sought to evaluate ergonomic strain among gynecologic oncologists... - Association between uterine serous carcinoma and breast cancerPaola A Gehrig
Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC 27599 7570, USA
Gynecol Oncol 94:208-11. 2004.... - Fertility-sparing surgery for ovarian low malignant potential tumorsGautam G Rao
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, J7.124, Dallas, TX 75390-9032, USA
Gynecol Oncol 98:263-6. 2005..CONCLUSION: Fertility-sparing surgery for ovarian LMP tumors is an option for motivated patients. Preservation of the contralateral adnexa increases the risk of recurrence, but surgical resection is usually curative... - Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervixShawna L Bull Phelps
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, J7 124, Dallas, TX 75390 9032, USA
Gynecol Oncol 107:316-9. 2007..The purpose of this study was to determine the outcomes of patients treated by this fertility-sparing strategy over an extended period of surveillance... - Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypesAlberto Mendivil
Division of Gynecologic Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Cancer Control 16:46-52. 2009..Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens... - Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) reviewDavid M Boruta
Department of Obstetrics, Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Gynecol Oncol 115:142-53. 2009..This review summarizes the available literature concerning UPSC in an effort to provide the clinician with information pertinent to its management... - Estrogen induction of telomerase activity through regulation of the mitogen-activated protein kinase (MAPK) dependent pathway in human endometrial cancer cellsChunxiao Zhou
Division of Gynecological Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina, USA
PLoS ONE 8:e55730. 2013..These findings suggest that E2-induction of telomerase activity is mediated via the MAPK pathway in human endometrial cancer cells... - Management of a persistent adnexal mass in pregnancy: what is the ideal surgical approach?Ursula Balthazar
Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7570, USA
J Minim Invasive Gynecol 18:720-5. 2011..To compare short-term and pregnancy-related outcomes of laparoscopy with laparotomy for management of a persistent second-trimester adnexal mass... - Surgical staging of ovarian low malignant potential tumorsGautam G Rao
Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Obstet Gynecol 104:261-6. 2004..4%) death occurred after a median follow-up of 28 (range, 1-208) months. CONCLUSION: Routine pelvic and para-aortic lymph node dissection is not necessary in the majority of women with ovarian low malignant potential tumors... - Extraskeletal myxoid chondrosarcoma: a report of a gynecologic caseMildred R Santacruz
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina, 4013 B Old Clinic Building, Chapel Hill, NC 27599, USA
Gynecol Oncol 98:498-501. 2005..Extraskeletal myxoid chondrosarcoma is a rare tumor that has been reported and discussed in neurosurgical, orthopedic, and otolaryngologic literature. We report a case of vulvar extraskeletal myxoid chondrosarcoma... - The role of optimal debulking in advanced stage serous carcinoma of the uterusKaren A Moller
UNC Chapel Hill, CB7570, Chapel Hill, NC 27599, USA
Gynecol Oncol 94:170-4. 2004..To evaluate the role of optimal surgical cytoreduction and postoperative therapy in women with advanced uterine serous carcinoma (USC)... - Uterine papillary serous carcinoma: a reviewPaola A Gehrig
University of North Carolina at Chapel Hill, Department of Obstetrics and Gynecology, CB 7570 MacNider Building, Chapel Hill, NC 27599 7570, USA
Expert Opin Pharmacother 8:809-16. 2007..There is a need for clinical trials to determine the optimal therapy for this cohort of patients... - High-grade squamous intraepithelial lesions: abbreviating posttreatment surveillanceElizabeth N Skinner
Department of Obstetrics and Gynecology, Division of Gynecology Oncology, University of North Carolina-Chapel Hill, CB 7570 Women's Hospital, Chapel Hill, NC 27599, USA
Obstet Gynecol 103:488-92. 2004..Lengthening the surveillance intervals could be beneficial to patients, while decreasing healthcare costs, without compromising the ability to detect and treat recurrent disease. LEVEL OF EVIDENCE: II-2.. - Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patientsNinh M La-Beck
UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Cancer Chemother Pharmacol 69:43-50. 2012..We previously reported that age, gender, body composition, and monocytes affect the clearance of other liposomal agents. Therefore, we evaluated how these factors affect the pharmacokinetics of PLD... - Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cellsChunxiao Zhou
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Mol Cancer Ther 2:789-95. 2003..This work suggests that rapamycin is a potentially useful targeted therapy for endometrial cancer and that loss of telomerase activity may be a good surrogate biomarker for assessing antitumor activity of rapamycin... - Weekly paclitaxel infusion as salvage therapy in ovarian cancerDavid M Boruta
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of North Carolina, Campus Box #7570, 4013 Old Clinic Building, Chapel Hill, NC 27599-7570, USA
Cancer Invest 21:675-81. 2003..The regimen is well tolerated with no cases of grade 4 neutropenia or worsening neuropathy in our population... - Endocervical curettage at conization to predict residual cervical adenocarcinoma in situJayanthi S Lea
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9032, USA
Gynecol Oncol 87:129-32. 2002..CONCLUSION: ECC performed at the time of conization may be a useful tool for predicting residual AIS in women considering fertility preservation...